Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor : A New Approach to Risk Factor ManagementMASON, R. Preston.Drugs (Basel). 2008, Vol 68, Num 7, pp 885-900, issn 0012-6667, 16 p.Article

Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidenceMASON, R. Preston.Atherosclerosis. 2002, Vol 165, Num 2, pp 191-199, issn 0021-9150, 9 p.Article

Molecular basis of differences among statins and a comparison with antioxidant vitaminsMASON, R. Preston.The American journal of cardiology. 2006, Vol 98, Num 11, issn 0002-9149, 34P-41P, SUPArticle

Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactionsPHILLIPS, Jane Ellen; MASON, R. Preston.Atherosclerosis. 2003, Vol 168, Num 2, pp 239-244, issn 0021-9150, 6 p.Article

Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery diseaseMASON, R. Preston.Pharmacotherapy. 2001, Vol 21, Num 9, pp 209S-215S, issn 0277-0008, 2Conference Paper

Membrane microdomains and vascular biology: Emerging role in atherogenesisMASON, R. Preston; JACOB, Robert F.Circulation (New York, N.Y.). 2003, Vol 107, Num 17, pp 2270-2273, issn 0009-7322, 4 p.Article

Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipineMASON, R. Preston.The American journal of cardiology. 2001, Vol 88, Num 10A, pp 2-6, issn 0002-9149Article

Effects of Calcium Channel and Renin-Angiotensin System Blockade on Intravascular and Neurohormonal Mechanisms of Hypertensive Vascular DiseaseMIZUNO, Yoshiko; JACOB, Robert F; MASON, R. Preston et al.American journal of hypertension. 2008, Vol 21, Num 10, pp 1076-1085, issn 0895-7061, 10 p.Article

A rationale for combination therapy in risk factor management : a mechanistic perspectiveMASON, R. Preston.The American journal of medicine. 2005, Vol 118, Num 12A, pp 54S-61S, issn 0002-9343Conference Paper

Atorvastatin Active Metabolite Inhibits Oxidative Modification of Small Dense Low-Density LipoproteinJACOB, Robert F; WALTER, Mary F; SELF-MEDLIN, Yehudi et al.Journal of cardiovascular pharmacology. 2013, Vol 62, Num 2, pp 160-166, issn 0160-2446, 7 p.Article

Biologic Activity of Carotenoids Related to Distinct Membrane Physicochemical InteractionsMCNULTY, Hyesun; JACOB, Robert F; MASON, R. Preston et al.The American journal of cardiology. 2008, Vol 101, Num 10, issn 0002-9149, 20D-29D, SUPArticle

7-Ketocholesterol forms crystalline domains in model membranes and murine aortic smooth muscle cellsPHILLIPS, Jane Ellen; GENG, Yong-Jian; MASON, R. Preston et al.Atherosclerosis. 2001, Vol 159, Num 1, pp 125-135, issn 0021-9150Conference Paper

Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black AmericansMASON, R. Preston; KALINOWSKI, Leszek; JACOB, Robert F et al.Circulation (New York, N.Y.). 2005, Vol 112, Num 24, pp 3795-3801, issn 0009-7322, 7 p.Article

Interactions biophysiques membranaires de l'amlodipine et propriétés antioxydantes = Membrane biophysical interactions of amlodipine result in antioxidant propertiesMASON, R. Preston; TRUMBORE, Mark W; MASON, Pamela E et al.Drugs (Basel). 2000, Vol 59, pp 9-16, issn 0012-6667, NS2Article

Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipineKAHN, Mark B; BOESZE-BATTAGLIA, Kathleen; STEPP, David W et al.American journal of physiology. Heart and circulatory physiology. 2005, Vol 57, Num 2, pp H591-H600, issn 0363-6135Article

Synergistic Effect of Amlodipine and Atorvastatin in Reversing LDL-Induced Endothelial DysfunctionMASON, R. Preston; KUBANT, Ruslan; HEEBA, Gehan et al.Pharmaceutical research. 2008, Vol 25, Num 8, pp 1798-1806, issn 0724-8741, 9 p.Article

Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variantsMASON, R. Preston; JACOB, Robert F; KUBANT, Ruslan et al.British journal of clinical pharmacology. 2012, Vol 74, Num 1, pp 141-146, issn 0306-5251, 6 p.Article

Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actionsMASON, R. Preston; WALTER, Mary F; DAY, Charles A et al.The American journal of cardiology. 2005, Vol 96, Num 5, pp 11F-23F, issn 0002-9149, SUPConference Paper

Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse modelKHAN, Sanjoy K; MALINSKI, Tadeusz; LOCKWOOD, Samuel F et al.Thrombosis research. 2010, Vol 126, Num 4, pp 299-305, issn 0049-3848, 7 p.Article

The editor's roundtable : Revisiting the role of beta blockers in hypertensionROBERTS, William C; BLACK, Henry R; BAKRIS, George L et al.The American journal of cardiology. 2007, Vol 100, Num 2, pp 253-267, issn 0002-9149, 15 p.Article

Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT StudyWALTER, Mary F; JACOB, Robert F; JEFFERS, Barrett et al.Journal of the American College of Cardiology. 2004, Vol 44, Num 10, pp 1996-2002, issn 0735-1097, 7 p.Article

Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and ruptureGENG, Yong-Jian; PHILLIPS, Jane Ellen; MASON, R. Preston et al.Biochemical pharmacology. 2003, Vol 66, Num 8, pp 1485-1492, issn 0006-2952, 8 p.Conference Paper

Loss of Arterial and Renal Nitric Oxide Bioavailability in Hypertensive Rats With Diabetes: Effect of β-BlockersMASON, R. Preston; KUBANT, Ruslan; JACOB, Robert F et al.American journal of hypertension. 2009, Vol 22, Num 11, pp 1160-1166, issn 0895-7061, 7 p.Article

Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease : The PREVENT StudyWALTER, Mary F; JACOB, Robert F; BJORK, Rebekah E et al.Journal of the American College of Cardiology. 2008, Vol 51, Num 12, pp 1196-1202, issn 0735-1097, 7 p.Article

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDsWALTER, Mary F; JACOB, Robert F; DAY, Charles A et al.Atherosclerosis. 2004, Vol 177, Num 2, pp 235-243, issn 0021-9150, 9 p.Article